Viridian Therapeutics, Inc. (VRDN) Stock Forecast
VRDN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.82 / 5 from 17 analysts
- Price target
- $36.75 average of analyst targets
- Upside to target
- +93.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.08
- 52-week range
- $13.30 – $33.78
VRDN analyst ratings
17 analystsNumber of analysts at each rating.
VRDN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VRDN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.02 | −$1.26 | −$0.78 | −$0.34 | −201.4% | 11 |
| Current fiscal year (2026) | −$3.94 | −$4.60 | −$3.41 | −$3.32 | −18.7% | 12 |
| Next fiscal year (2027) | −$2.75 | −$4.10 | −$1.70 | −$3.94 | +30.1% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VRDN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.7M | $0 | $15.0M | −93.4% | 14 |
| Current fiscal year (2026) | $24.4M | $12.0M | $45.4M | −65.6% | 14 |
| Next fiscal year (2027) | $233.6M | $113.5M | $482.7M | +857.5% | 14 |
VRDN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VRDN revenue: reported and forecast
VRDN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.93 | −$0.99 | −$0.99 | −$0.97 | −$1.02 | +10.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$3.80 | −$3.95 | −$3.95 | −$3.88 | −$3.94 | +3.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.63 | −$2.77 | −$2.77 | −$2.74 | −$2.75 | +4.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VRDN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VRDN beat in 6 of 12.
What analysts expect from VRDN
17 analysts cover Viridian Therapeutics; their consensus rating is strong buy (4.82 on a 1–5 scale, where 5 is a strong buy). The average price target is $36.75, 93.1% above the latest close of $19.03. Analysts expect earnings of −$3.94 per share for 2026, −18.7% from a year earlier. For 2027 the average estimate is −$2.75 per share on revenue of $233.6 million. Viridian Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: VRDN income statement, VRDN key metrics, VRDN chart. See the VRDN stock overview for the latest quote and news.
VRDN forecast FAQ
What is Viridian Therapeutics's price target?
The average analyst price target for Viridian Therapeutics is $36.75, 93.1% above the latest close of $19.03.
Is Viridian Therapeutics a buy, hold or sell?
Of 17 analysts covering Viridian Therapeutics, 14 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Viridian Therapeutics's EPS forecast?
Analysts forecast −$3.94 per share for 2026 (range −$4.60 to −$3.41); for 2027 the estimate is −$2.75.
What is Viridian Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $24.4 million, growth of −65.6%; for 2027 it is $233.6 million.
When does Viridian Therapeutics report earnings?
Viridian Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-1.08.
Does Viridian Therapeutics usually beat earnings estimates?
Viridian Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.